MARKET

SKYE

SKYE

Skye Bioscience
NASDAQ
0.8000
-0.0344
-4.12%
After Hours: 0.8353 +0.0353 +4.41% 19:42 12/26 EST
OPEN
0.8000
PREV CLOSE
0.8344
HIGH
0.8210
LOW
0.7600
VOLUME
551.92K
TURNOVER
--
52 WEEK HIGH
5.75
52 WEEK LOW
0.7600
MARKET CAP
25.65M
P/E (TTM)
-0.6203
1D
5D
1M
3M
1Y
5Y
1D
Why Multi Ways Holdings Shares Are Trading Higher By Around 60%; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
Skye Bioscience Collaborates with Halozyme on Nimacimab Delivery
TipRanks · 4d ago
Skye Bioscience Enters Non-Exclusive Licensing And Collaboration Agreement With Halozyme For Subcutaneous Nimacimab Using ENHANZE Technology
Benzinga · 4d ago
SKYE BIOSCIENCE INC - HALOZYME GRANTS LICENSE FOR ENHANZE TECHNOLOGY TO SKYE BIOSCIENCE - SEC FILING
Reuters · 4d ago
Skye Bioscience Signs Collaboration and License Agreement with Halozyme
Reuters · 4d ago
Investors File Class Action Lawsuit Against Skye Bioscience Inc
Reuters · 4d ago
Weekly Report: what happened at SKYE last week (1215-1219)?
Weekly Report · 5d ago
Shareholders that lost money on Skye Bioscience, Inc.(SKYE) should contact The Gross Law Firm about pending Class Action - SKYE
Barchart · 5d ago
More
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

Webull offers Skye Bioscience Inc stock information, including NASDAQ: SKYE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SKYE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SKYE stock methods without spending real money on the virtual paper trading platform.